Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ABHI (Association of British Health-Care Industries) seeks progress with NICE (UK National Institute for Clinical Excellence) outside inquiry

This article was originally published in Clinica

Executive Summary

The Association of British Health-Care Industries (ABHI), the UK's leading association for the medical systems industry, has not been called to the oral sessions of the UK parliamentary inquiry into the performance of the National Institute for Clinical Excellence, due to take place later this month. The fact that its pharmaceutical industry counterpart - the Association of the British Pharmaceutical Industry (ABPI) - has, can be explained by the different relationship that exists between the UK's official clinical- and cost-effectiveness assessment body and the two main industries it affects, but does not mean that there is no room for improvement in NICE's assessment of devices.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT064191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel